This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Adaptive Biotechnologies , which develops technology to assess the immune response, posted $154.3 Net loss for 2021 came in at $207.3 million in the fourth quarter, up 26%, with a net loss of $61.4 Adaptive moved into its new headquarters in September. Co-founders Harlan (left) and Chad Robins on the new plaza. million in 2020.
In a region better known for its tech startups and legions of software engineers, it’s biotech companies that have helped lead a recent IPO boom in the state of Washington, accounting for eight of 11 firms joining the public markets via a traditional IPO over the past year. based biotech company went public. Absci Photo).
Formerly known as M3 Biotechnology, the company is led by Dr. Leen Kawas , a 35-year-old CEO who will be the first woman to guide a company to an initial public offering in Washington state in more than two decades. In its IPO paperwork, Athira reported a net loss of $5.2 billion in the largest software IPO ever.
The company, previously known as M3 Biotechnology, is led by Dr. Leen Kawas , a 35-year-old entrepreneur originally from Jordan. In its IPO paperwork, Athira reports a net loss of $5.2 It would be the first Seattle biotech to go public since Adaptive Biotechnologies IPO’d last year. million in 2019, and a loss of $3.8
million net loss and $132.5 million net loss and $94.8 Singh previously co-founded travel expense software giant Concur and brought on fellow Concur co-founder Mike Hilton as chief product officer at Accolade, which originally launched back in 2007. It plans to trade on the Nasdaq exchange under the ticker ACCD. Vancouver, Wash.-based
Banzai , a Seattle marketing software startup, announced Thursday that it will go public after it agreed to merge with a special-purpose acquisition company. Seattle businesses including Porch, Nautilus Biotechnology, Rover and Leafly have all gone public via SPAC within the last two years. Banzai CEO Joe Levy. Banzai Photo).
Susan Wyrick of Sana Biotechnology. LinkedIn Photo) — Susan Wyrick , senior vice president of finance and accounting at Sana Biotechnology , is serving as acting chief financial officer, treasurer, and principal accounting officer for the publicly traded company. — There’s new leadership at CTL , a Beaverton, Ore.,
It’s the latest privately-held company to test the public markets amid a rush of IPOs in recent months, particularly in biotech and software , despite the ongoing pandemic. ” Athira, previously known as M3 Biotechnology, plans to double the size of its 20-person team as it relocates into a larger facility in Bothell, Wash.
Their joint work on a process for cloning genes in microorganisms resulted in three patents that formed the foundation of the nascent biotechnology industry. SourceForge, the largest site for open source software development, lists over 40,000 current projects. Fixing software bugs is eminently suited to distributed projects.
Nautilus Biotechnology co-founders Sujal Patel (left) and Parag Mallick. Nautilus Biotechnology is emerging as Seattle’s newest publicly traded company this week, taking advantage of the mania over SPACs to raise $345 million to fuel a new approach that could accelerate biomedical research and transform drug development.
Nautilus Biotechnology co-founders Sujal Patel (left) and Parag Mallick. Nautilus Biotechnology , a Seattle-based biotech startup led by Isilon co-founder Sujal Patel , is the latest company to go public using a special purpose acquisition company, or SPAC. Nautilus Photo).
Evans’s involvement in the telecoms industry began with her work as a software engineer in the early 1980s. Chief Executive and Director of SAMI Consulting , Gill Ringland, has an impressive career history that has spanned physics, software, information technology, strategy, and future thinking. Gill Ringland. Twitter: @LeadThought.
We organize all of the trending information in your field so you don't have to. Join 83,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content